Brain Imaging Modalities Market Size is projected to reach $19.01 billion by 2031, growing at a CAGR of 5.71%: Straits Research

According to the research, the global brain imaging modalities market size was worth $12.19 billion in 2022 and is predicted to reach $19.01 billion by the end of 2031. During the projected period 2023-2031, the market is estimated to develop at a CAGR of 5.71%, One of the most lucrative markets may be in North America, which is one of the many important regions.

 | Quelle: Straits Research Straits Research

New York, United States, Aug. 07, 2023 (GLOBE NEWSWIRE) -- In the discipline of neurological testing, imaging tools of the brain are utilised for the purpose of identifying anomalies in the neurons being tested. Neurological illnesses such as Parkinson's disease, epilepsy, brain tumours, Alzheimer's disease, and sleep problems are all caused by abnormalities in the growth of neurons. Other neurological disorders include dementia and sleep disturbances. Functional brain imaging devices are an excellent option to invasive neurosurgery in a number of clinical situations.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/brain-imaging-modalities-market/request-sample

 

Increase in Brain Cancer

The expansion of the overall brain imaging market is anticipated to be driven in large part by the rising rates of neurodegenerative illnesses and the rising prevalence of brain cancer throughout the world. It is also anticipated that the introduction of novel products from major players in the imaging segment would boost the overall market for brain imaging.

One of the most important aspects that is predicted to drive the market during the forecast period is the rising number of traffic accidents that are occurring all over the world. One of the drivers that is expected to increase the revenue of the brain imaging market is the technological advantages in the imaging techniques. Another driver is the availability of reimbursement programmes for various types of imaging tests, including brain imaging tests. Both of these factors are expected to increase.

Development of Healthcare Diagnostics

It is anticipated that the continuously expanding healthcare diagnostics and imaging segment as well as novel initiatives for the management of neurological diseases would provide increasing potential for growth in the global functional brain imaging systems market. In addition, an increase in the number of patients requiring critical care for brain aneurysms and traumatic brain injuries is driving up the need for functional brain imaging equipment.

It is also anticipated that increasing applications of functional brain imaging systems for the prevention of brain haemorrhage in hospitals and ambulatory care centres under the supervision of authorised caregivers would drive the expansion of the market.

The use of innovative radioactive biomarkers in conjunction with the appropriate and tried-and-true equipment for functional brain imaging is helping to increase the rate of acceptance among surgeons, doctors, and oncologists alike. Patients have also shown a high level of acceptability for functional brain imaging systems as a result of the large value structure that these technologies offer in the treatment of brain-related diseases.


Report Scope

Report Metric Details
Market Size by 2031 USD 19.01 billion
Market Size in 2022 USD 12.19 billion
CAGR 5.71% (2023-2031)
Historical Data 2020-2021
Base Year 2022
Forecast Period 2023-2031
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Imaging Type, Patient Type, End User
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Varian Medical Systems,General Electric Company, Siemens AG, Philips Healthcare, and Toshiba Medical Systems. Siemens, Philips Healthcare, Toshiba medical systems, Hitachi Medical systems, MR Solutions,  Esaote SpA and Sanrad Medical Systems Pvt. Ltd
Key Market Opportunities Development of Healthcare Diagnostics to Spur Market Opportunities
Key Market Drivers Increase in Brain Cancer to Foster Market Growth

Buy Now Full Report @ https://straitsresearch.com/buy-now/brain-imaging-modalities-market 


Regional Overview of Brain Imaging Modalities Market

One of the most lucrative markets may be in North America, which is one of the many important regions. The rise has been backed, to a considerable extent, by significant investments made in the healthcare business as well as the implementation of cutting-edge functional imaging technology. It is anticipated that the United States will continue to see substantial growth during the projection period, which will allow it to maintain its dominant position in the North American region in 2020 with a total market share of 82.9 percent. The existence of a well-established and continuously expanding healthcare system as well as large functional brain imaging system providers in the nation are the primary factors propelling the expansion of this market.

Key Highlights

  • According to the research, the global brain imaging modalities market size was worth $12.19 billion in 2022 and is predicted to reach $19.01 billion by the end of 2031. During the projected period 2023-2031, the market is estimated to develop at a CAGR of 5.71%.
  • Rise in brain cancer fuelling the market
  • Rise in traffic accidents is driving the market growth.
  • Continuous expansion of healthcare diagnostics are a great opportunity for the market to grow.
  • Based on imaging type, the global brain imaging market is segmented as: Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT).
  • Based on Patient Type market is segmented into- Adults and Paediatrics and Infants.
  • Based on end user, the global brain imaging market is segmented as: Pharmaceutical Companies, Contract research organization (CRO’s), Biotech Companies, Research Institutes.
  • One of the most lucrative markets may be in North America, which is one of the many important regions. The rise has been backed, to a considerable extent, by significant investments made in the healthcare business as well as the implementation of cutting-edge functional imaging technology.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/brain-imaging-modalities-market/request-sample 


Competitors in Brain Imaging Modalities Market

  • Varian Medical Systems
  • General Electric Company
  • Siemens AG
  • Philips Healthcare
  • Toshiba medical systems
  • Hitachi Medical systems
  • MR Solutions
  • Esaote SpA
  • Sanrad Medical Systems Pvt. Ltd

Segmentation of Brain Imaging Modalities Market

By Imaging Type

  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Magnetic resonance imaging (MRI)
  • single photon emission computed tomography (SPECT) 

By Patient Type

  • Adults and Paediatrics
  • Infants

By End User

  • Pharmaceutical Companies
  • Contract research organization (CRO’s)
  • Biotech Companies
  • Research Institutes 

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

TABLE OF CONTENT

  1. EXECUTIVE SUMMARY
  2. RESEARCH SCOPE & SEGMENTATION
    1. RESEARCH OBJECTIVES
    2. MARKET DEFINITION
    3. LIMITATIONS & ASSUMPTIONS
    4. MARKET SCOPE & SEGMENTATION
    5. CURRENCY & PRICING CONSIDERED
  3. MARKET OPPORTUNITY ASSESSMENT
    1. EMERGING REGIONS / COUNTRIES
    2. EMERGING COMPANIES
    3. EMERGING APPLICATIONS / END USE
    4. INVESTMENT LANDSCAPE
    5. NEW BUSINESS MODELS / REVENUE STREAMS
    6. TAM
  4. MARKET TRENDS
    1. DRIVERS
    2. MARKET WARNING FACTORS
    3. LATEST MACRO ECONOMIC INDICATORS
    4. GEOPOLITICAL IMPACT
    5. HUMAN FACTORS
    6. TECHNOLOGY FACTORS
  5. MARKET ASSESSMENT
    1. PORTERS FIVE FORCES ANALYSIS
    2. VALUE CHAIN ANALYSIS
    3. SALES AND DISTRIBUTION CHANNEL ANALYSIS
    4. CASE STUDY ANALYSIS
    5. PATENT ANALYSIS
    6. M & A AGREEMENTS & COLLABRATION ANALYSIS
  6. ESG TRENDS
  7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE ANALYSIS
    1. GLOBAL BRAIN IMAGING MODALITIES MARKET INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
  8. NORTH AMERICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
    5. U.S.
      1. BY IMAGING TYPE
        1. INTRODUCTION
          1. IMAGING TYPE BY VALUE
        2. COMPUTED TOMOGRAPHY (CT)
          1. BY VALUE
        3. POSITRON EMISSION TOMOGRAPHY (PET)
          1. BY VALUE
        4. MAGNETIC RESONANCE IMAGING (MRI)
          1. BY VALUE
        5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
          1. BY VALUE
      2. BY PATIENT TYPE
        1. INTRODUCTION
          1. PATIENT TYPE BY VALUE
        2. ADULTS AND PAEDIATRICS
          1. BY VALUE
        3. INFANTS
          1. BY VALUE
      3. BY END USER
        1. INTRODUCTION
          1. END USER BY VALUE
        2. PHARMACEUTICAL COMPANIES
          1. BY VALUE
        3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
          1. BY VALUE
        4. BIOTECH COMPANIES
          1. BY VALUE
        5. RESEARCH INSTITUTES 
          1. BY VALUE
    6. CANADA
  9. EUROPE MARKET ANALYSIS
    1. INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
    5. U.K.
      1. BY IMAGING TYPE
        1. INTRODUCTION
          1. IMAGING TYPE BY VALUE
        2. COMPUTED TOMOGRAPHY (CT)
          1. BY VALUE
        3. POSITRON EMISSION TOMOGRAPHY (PET)
          1. BY VALUE
        4. MAGNETIC RESONANCE IMAGING (MRI)
          1. BY VALUE
        5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
          1. BY VALUE
      2. BY PATIENT TYPE
        1. INTRODUCTION
          1. PATIENT TYPE BY VALUE
        2. ADULTS AND PAEDIATRICS
          1. BY VALUE
        3. INFANTS
          1. BY VALUE
      3. BY END USER
        1. INTRODUCTION
          1. END USER BY VALUE
        2. PHARMACEUTICAL COMPANIES
          1. BY VALUE
        3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
          1. BY VALUE
        4. BIOTECH COMPANIES
          1. BY VALUE
        5. RESEARCH INSTITUTES 
          1. BY VALUE
    6. GERMANY
    7. FRANCE
    8. SPAIN
    9. ITALY
    10. RUSSIA
    11. NORDIC
    12. BENELUX
    13. REST OF EUROPE
  10. APAC MARKET ANALYSIS
    1. INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
    5. CHINA
      1. BY IMAGING TYPE
        1. INTRODUCTION
          1. IMAGING TYPE BY VALUE
        2. COMPUTED TOMOGRAPHY (CT)
          1. BY VALUE
        3. POSITRON EMISSION TOMOGRAPHY (PET)
          1. BY VALUE
        4. MAGNETIC RESONANCE IMAGING (MRI)
          1. BY VALUE
        5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
          1. BY VALUE
      2. BY PATIENT TYPE
        1. INTRODUCTION
          1. PATIENT TYPE BY VALUE
        2. ADULTS AND PAEDIATRICS
          1. BY VALUE
        3. INFANTS
          1. BY VALUE
      3. BY END USER
        1. INTRODUCTION
          1. END USER BY VALUE
        2. PHARMACEUTICAL COMPANIES
          1. BY VALUE
        3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
          1. BY VALUE
        4. BIOTECH COMPANIES
          1. BY VALUE
        5. RESEARCH INSTITUTES 
          1. BY VALUE
    6. KOREA
    7. JAPAN
    8. INDIA
    9. AUSTRALIA
    10. TAIWAN
    11. SOUTH EAST ASIA
    12. REST OF ASIA-PACIFIC
  11. MIDDLE EAST AND AFRICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
    5. UAE
      1. BY IMAGING TYPE
        1. INTRODUCTION
          1. IMAGING TYPE BY VALUE
        2. COMPUTED TOMOGRAPHY (CT)
          1. BY VALUE
        3. POSITRON EMISSION TOMOGRAPHY (PET)
          1. BY VALUE
        4. MAGNETIC RESONANCE IMAGING (MRI)
          1. BY VALUE
        5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
          1. BY VALUE
      2. BY PATIENT TYPE
        1. INTRODUCTION
          1. PATIENT TYPE BY VALUE
        2. ADULTS AND PAEDIATRICS
          1. BY VALUE
        3. INFANTS
          1. BY VALUE
      3. BY END USER
        1. INTRODUCTION
          1. END USER BY VALUE
        2. PHARMACEUTICAL COMPANIES
          1. BY VALUE
        3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
          1. BY VALUE
        4. BIOTECH COMPANIES
          1. BY VALUE
        5. RESEARCH INSTITUTES 
          1. BY VALUE
    6. TURKEY
    7. SAUDI ARABIA
    8. SOUTH AFRICA
    9. EGYPT
    10. NIGERIA
    11. REST OF MEA
  12. LATAM MARKET ANALYSIS
    1. INTRODUCTION
    2. BY IMAGING TYPE
      1. INTRODUCTION
        1. IMAGING TYPE BY VALUE
      2. COMPUTED TOMOGRAPHY (CT)
        1. BY VALUE
      3. POSITRON EMISSION TOMOGRAPHY (PET)
        1. BY VALUE
      4. MAGNETIC RESONANCE IMAGING (MRI)
        1. BY VALUE
      5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
        1. BY VALUE
    3. BY PATIENT TYPE
      1. INTRODUCTION
        1. PATIENT TYPE BY VALUE
      2. ADULTS AND PAEDIATRICS
        1. BY VALUE
      3. INFANTS
        1. BY VALUE
    4. BY END USER
      1. INTRODUCTION
        1. END USER BY VALUE
      2. PHARMACEUTICAL COMPANIES
        1. BY VALUE
      3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
        1. BY VALUE
      4. BIOTECH COMPANIES
        1. BY VALUE
      5. RESEARCH INSTITUTES 
        1. BY VALUE
    5. BRAZIL
      1. BY IMAGING TYPE
        1. INTRODUCTION
          1. IMAGING TYPE BY VALUE
        2. COMPUTED TOMOGRAPHY (CT)
          1. BY VALUE
        3. POSITRON EMISSION TOMOGRAPHY (PET)
          1. BY VALUE
        4. MAGNETIC RESONANCE IMAGING (MRI)
          1. BY VALUE
        5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
          1. BY VALUE
      2. BY PATIENT TYPE
        1. INTRODUCTION
          1. PATIENT TYPE BY VALUE
        2. ADULTS AND PAEDIATRICS
          1. BY VALUE
        3. INFANTS
          1. BY VALUE
      3. BY END USER
        1. INTRODUCTION
          1. END USER BY VALUE
        2. PHARMACEUTICAL COMPANIES
          1. BY VALUE
        3. CONTRACT RESEARCH ORGANIZATION (CRO’S)
          1. BY VALUE
        4. BIOTECH COMPANIES
          1. BY VALUE
        5. RESEARCH INSTITUTES 
          1. BY VALUE
    6. MEXICO
    7. ARGENTINA
    8. CHILE
    9. COLOMBIA
    10. REST OF LATAM
  13. COMPETITIVE ASSESSMENT
    1. ADOPTION MATRIX
    2. BRAIN IMAGING MODALITIES MARKET SHARE BY MANUFACTURERS
    3. BRAIN IMAGING MODALITIES MARKET RANKING BY REVENUE FOR MANUFACTURERS
    4. AVERAGE PRICE BY MANUFACTURERS
    5. VENDOR FOOTPRINT ANALYSIS
  14. MARKET PLAYERS ASSESSMENT
    1. VARIAN MEDICAL SYSTEMS
      1. OVERVIEW
      2. BUSINESS INFORMATION
      3. REVENUE
      4. ASP
      5. GROSS MARGIN
      6. SWOT ANALYSIS
      7. RECENT DEVELOPMMENTS
    2. GENERAL ELECTRIC COMPANY
    3. SIEMENS AG
    4. PHILIPS HEALTHCARE
    5. TOSHIBA MEDICAL SYSTEMS
    6. SIEMENS
    7. HITACHI MEDICAL SYSTEMS
    8. MR SOLUTIONS
    9. ESAOTE SPA
    10. SANRAD MEDICAL SYSTEMS PVT. LTD
  15. RESEARCH METHODOLOGY
    1. RESEARCH DATA
      1. SECONDARY DATA
        1. MAJOR SECONDARY SOURCES
        2. KEY DATA FROM SECONDARY SOURCES
      2. PRIMARY DATA
        1. KEY DATA FROM PRIMARY SOURCES
        2. BREAKDOWN OF PRIMARIES
      3. SECONDARY AND PRIMARY RESEARCH
        1. KEY INDUSTRY INSIGHTS
    2. MARKET SIZE ESTIMATION
      1. BOTTOM-UP APPROACH
      2. TOP-DOWN APPROACH
      3. MARKET PROJECTION
    3. RESEARCH ASSUMPTIONS
      1. ASSUMPTIONS
    4. LIMITATIONS
    5. RISK ASSESSMENT
  16. APPENDIX
    1. DISCUSSION GUIDE
    2. CUSTOMIZATION OPTIONS
    3. RELATED REPORTS
  17. DISCLAIMER


Table of Content and Figure @ https://straitsresearch.com/report/brain-imaging-modalities-market/toc


Recent Developments

  • At RSNA 2020 in November 2020, Philips unveiled IntelliSpace Portal 12, a next-generation Advanced Visualization Workspace with AI capabilities. To support diagnostic process, including follow-up and communication across cardiology, pulmonology, cancer, and neurology, IntelliSpace Portal now includes a strong set of new AI-assisted quantitative evaluation and automatic results production tools. Its AI-assisted pulmonary capabilities include the evaluation of COVID-19-related complicated lung diseases.
  • Siemens unveiled its smallest and lightest whole-body MRI in November 2020.
  • In October 2020, MR Solutions secured a purchase order for their preclinical equipment worth up to USD 10 million from prestigious institutions.


News Media

Brain Imaging Modalities Market to Grow at a CAGR of 5.71% During 2022–2031

Brain Disease Modalities and Software Market to Grow at a CAGR of 6.50% During 2019–2026


Have a Look at the Related Research Report

Brain Disease Modalities and Software Market: Information by Offering (Patient Type, Adults, Paediatrics & Infants), Application (Traumatic Brain Injury), and Region — Forecast till 2030

Deep Brain Stimulation Devices Market: Information by Application (Parkinson's Disease, Epilepsy), End-User (Hospitals, Neurological Clinics), and Region—Forecast till 2031

Wireless Brain Sensors Market: Information by Product (Electroencephalography Devices), Therapeutic Application (Traumatic Brain Injuries), End-Users, and Region — Forecast till 2031

Concussion Market: Information by Treatment (X-ray, Treatment, Magnetic Resonance Imaging (MRI) Devices), End-User (Hospitals, Clinics, Medical Camps), and Region-Forecast till 2031

Brain Monitoring Market: Information by Product (Cerebral Oximeters, Accessories), Application (Epilepsy, Dementia), End-User (Hospitals), and Regions-Forecast till 2031


About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.


For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter


Tags

Brain Imaging Modalities brain imaging devices brain imaging systems brain imaging industry brain imaging tests CT PET MRI SPECT

Weiterführende Links